1. Home
  2. EXEL vs SEIC Comparison

EXEL vs SEIC Comparison

Compare EXEL & SEIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXEL
  • SEIC
  • Stock Information
  • Founded
  • EXEL 1994
  • SEIC 1968
  • Country
  • EXEL United States
  • SEIC United States
  • Employees
  • EXEL N/A
  • SEIC N/A
  • Industry
  • EXEL Biotechnology: Biological Products (No Diagnostic Substances)
  • SEIC Investment Bankers/Brokers/Service
  • Sector
  • EXEL Health Care
  • SEIC Finance
  • Exchange
  • EXEL Nasdaq
  • SEIC Nasdaq
  • Market Cap
  • EXEL 9.8B
  • SEIC 9.7B
  • IPO Year
  • EXEL 2000
  • SEIC N/A
  • Fundamental
  • Price
  • EXEL $43.04
  • SEIC $85.26
  • Analyst Decision
  • EXEL Buy
  • SEIC Buy
  • Analyst Count
  • EXEL 18
  • SEIC 5
  • Target Price
  • EXEL $38.76
  • SEIC $87.60
  • AVG Volume (30 Days)
  • EXEL 3.9M
  • SEIC 1.2M
  • Earning Date
  • EXEL 05-13-2025
  • SEIC 07-23-2025
  • Dividend Yield
  • EXEL N/A
  • SEIC 1.11%
  • EPS Growth
  • EXEL 237.58
  • SEIC 25.40
  • EPS
  • EXEL 2.20
  • SEIC 4.59
  • Revenue
  • EXEL $2,298,922,000.00
  • SEIC $2,164,916,000.00
  • Revenue This Year
  • EXEL $10.39
  • SEIC $6.11
  • Revenue Next Year
  • EXEL $10.74
  • SEIC $4.57
  • P/E Ratio
  • EXEL $19.53
  • SEIC $18.57
  • Revenue Growth
  • EXEL 24.49
  • SEIC 10.33
  • 52 Week Low
  • EXEL $20.40
  • SEIC $62.38
  • 52 Week High
  • EXEL $48.85
  • SEIC $87.25
  • Technical
  • Relative Strength Index (RSI)
  • EXEL 59.93
  • SEIC 63.52
  • Support Level
  • EXEL $42.21
  • SEIC $83.29
  • Resistance Level
  • EXEL $43.75
  • SEIC $86.34
  • Average True Range (ATR)
  • EXEL 1.60
  • SEIC 1.50
  • MACD
  • EXEL -0.09
  • SEIC -0.14
  • Stochastic Oscillator
  • EXEL 53.96
  • SEIC 69.23

About EXEL Exelixis Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

About SEIC SEI Investments Company

SEI Investments provides investment processing, management, and operations services to financial institutions, asset managers, asset owners, and financial advisors in four material segments: private banks, investment advisors, institutional investors, and investment managers. SEI also has a minority interest in LSV Asset Management, a value equity asset manager with about $87 billion in assets under management. As of December 2024, SEI (including LSV) manages, administers, or advises about $1.6 trillion in assets.

Share on Social Networks: